This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.

Esta invenção relaciona-se a uns 24 formulários de dosage estendidos hora do formulation e da unidade do dosage da liberação disso do hydrochloride do venlafaxine, um antidepressivo, que forneça o controle melhor de níveis do plasma de sangue do que os formulations convencionais da tabuleta que devem ser administrados dois ou mais cronometram um dia e fornecem mais mais uma incidência mais baixa do nausea e de vomiting do que as tabuletas convencionais. Mais particularmente, a invenção compreende um formulation prolongado da liberação do hydrochloride do venlafaxine que compreende uma quantidade therapeutically eficaz do hydrochloride do venlafaxine nos spheroids compreendidos do hydrochloride do venlafaxine, da celulose microcrystalline e, opcionalmente, do hydroxypropylmethylcellulose revestido com uma mistura da celulose ethyl e do hydroxypropylmethylcellulose.

 
Web www.patentalert.com

< Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent for treatment of depression or anxiety

< On demand administration of clomipramine and salts thereof to treat premature ejaculation

> Methods for treating neuropsychiatric disorders

> Dual enhancer composition for topical and transdermal drug delivery

~ 00038